Oncology Consults: A CME/CE Learning Module on Metastatic Melanoma is organized by Johns Hopkins University School of Medicine and would be held during May 20, 2016 - May 20, 2018.
This activity is designed for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with metastatic melanoma. No prerequisites required. This CME Conference has been approved with a maximum of 5.0 AMA PRA Category 1 Credits.
Recent advances in the understanding of the immunology and molecular biology of melanoma have changed the therapeutic landscape of patients with metastatic melanoma. Research has led to the introduction of breakthrough drugs that work by targeting the mitogen-activated protein kinase (MAPK) pathway in melanoma cells, which harbors BRAF mutations (targeted therapy) or turning off normal brakes (CTLA-4, PD-1) in the immune system (checkpoint inhibitors). This new generation of therapies, which has demonstrated improved objective response rates and overall survival in large randomized clinical trials, is the focus of this learning initiative. It will help guide healthcare professionals who treat patients with metastatic melanoma, including oncologists, oncology nurses, and oncology physician assistants. This interactive case activity will provide a thorough a review of the emerging knowledge about the molecular biology and immunology of metastatic melanoma and the new systemic therapies that have been built on that knowledge. It also will discuss the latest clinical evidence supporting the place of these drugs in the melanoma treatment paradigm. In addition we will discuss the unique side effects of these new treatments.
After participating in this activity, the participant will demonstrate the ability to:
• EVALUATE the evidence-based findings regarding the new and emergent systemic therapies for patients with metastatic melanoma.
• ASSESS the role of immuno- and targeted therapy in the treatment paradigm for patients with metastatic melanoma.
• IDENTIFY the criteria for recommending specific immunotherapeutic and targeted therapies for patients with metastatic melanoma based on their presentation, laboratory, radiological, and histological findings.
Additional details will be posted as soon as they are available.